Evidence map›Paper›PMID 35930296›Full record

ArticleHead & neck2022

Oncologic outcomes of salvage surgery and immune checkpoint inhibitor therapy in recurrent head and neck squamous cell carcinoma: A single-institution retrospective study.

Neeraja Konuthula, Olivia A Do, Ted Gobillot, Cristina P Rodriguez, Neal D Futran, Jeffrey Houlton, Brittany R Barber

Abstract read
PubMed Publisher
In one paragraph

Article in Head & neck, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Neeraja KonuthulaDepartment of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-9691-9331
Olivia A DoDepartment of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, Washington, USA.ORCID 0000-0003-3483-7522
Ted GobillotDepartment of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, Washington, USA.
Cristina P RodriguezDepartment of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, Washington, USA.
Neal D FutranDepartment of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, Washington, USA.
Jeffrey HoultonDepartment of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, Washington, USA.ORCID 0000-0003-2423-658X
Brittany R BarberDepartment of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, Washington, USA.
University of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSurvival outcomes in recurrent head and neck squamous cell carcinoma (HNSCC) are poor. This study aimed to compare survival outcomes between salvage surgery and immunotherapy in patients with recurrent advanced HNSCC.

methodsPatients with advanced stage (stage III or IV) recurrent HNSCC following treatment with platinum-based chemotherapy were included. Survival was estimated using the Kaplan-Meier method, and Cox regression was used for multivariate logistic regression.

resultsTwo-year overall survival after salvage surgery was 68.6% and after immunotherapy patients was 24.6%. Multivariate logistic regression showed that salvage surgery was associated with improved survival without statistical significance (hazard ratio [HR] 0.12, p = 0.25). Subgroup analysis of patients with oral cavity/oropharyngeal cancer noted improved survival with salvage surgery over immunotherapy (HR 0.006, p = 0.01) and decreased survival with neutrophil-to-lymphocyte ratio (NLR) > 5 (HR 6.4, p = 0.02).

conclusionOur retrospective single-institutional data suggest that resectable advanced stage recurrent HNSCC may have improved survival with salvage surgery in appropriately selected patients, but larger prospective studies are required.

Indexed as

Head and Neck NeoplasmsMouth NeoplasmsHumansImmune Checkpoint InhibitorsNeoplasm Recurrence, LocalRetrospective StudiesSalvage TherapySquamous Cell Carcinoma of Head and NeckImmune Checkpoint Inhibitorsimmunotherapyoutcomespembrolizumabrecurrent head and neck cancersalvage surgery

Identifiers

PMID35930296
OpenAlexW4289947215

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.